Ready 8-Ks
2
Latest filing
September 8, 2026, 4:06 PM ET
Top materiality
0.65
Event mix
earnings ×1 · other_material ×1
Sentiment
0 pos · 0 neg · 2 neu
Recent 8-K filings for BRVE
Highest-materiality recent filing
Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing
- Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.
- Net loss $15.0M; attributed to common stockholders $18.6M ($2.51/sh) vs $0.4M ($0.14/sh) in Q2 2025.
-
Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing
Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.
-
Braveheart Bio files amended charter and bylaws post-IPO, authorizing 500M common shares
Second amended and restated certificate of incorporation filed with Delaware on Aug 7, 2026, effective immediately prior to IPO completion.
Materiality & sentiment trend
Max materiality 0.65 · Median 0.47 · Most common event earnings